Plus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
October 31, 2023 at 04:02 pm EDT
Share
Plus Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 3.22 million compared to USD 5.22 million a year ago. Basic loss per share from continuing operations was USD 1 compared to USD 2.85 a year ago. Diluted loss per share from continuing operations was USD 1 compared to USD 2.85 a year ago.
For the nine months, net loss was USD 9.51 million compared to USD 14.62 million a year ago. Basic loss per share from continuing operations was USD 3.54 compared to USD 9.22 a year ago. Diluted loss per share from continuing operations was USD 3.54 compared to USD 9.22 a year ago.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.